Начало・Списък с акции・Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

31.59 3.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

29.15

Максимум

30.85

Ключови измерители
By Trading Economics
Приходи	8.9M -99M
Продажби	779K 21M
EPS	-1.69
Марж на печалбата	-477.735
Служители	539
EBITDA	23M -98M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+34.25% upside

Дивиденти
By Acuity
Следващи печалби	29.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	746M 2.2B
Предишно отваряне	27.91
Предишно затваряне	31.59

Настроения в новините

By Acuity

50%

151 / 340 Класиране в Healthcare

Agios Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 20:06 ч. UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31.07.2026 г., 22:51 ч. UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30.07.2026 г., 20:08 ч. UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29.07.2026 г., 20:51 ч. UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28.07.2026 г., 20:02 ч. UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27.07.2026 г., 20:01 ч. UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24.07.2026 г., 23:21 ч. UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22.07.2026 г., 22:41 ч. UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21.07.2026 г., 19:01 ч. UTC

News

Event

Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Сравнение с други в отрасъла

Ценова промяна

Agios Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

34.25% нагоре

12-месечна прогноза

Среден 41 USD 34.25%

Висок 55 USD

Нисък 31 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Agios Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Agios Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

151 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.